AngioDynamics, a vascular-focused medical technology company, and The PERT Consortium, a multidisciplinary organization focused on improving pulmonary embolism care, have launched the ALPHA-PE Research Fund, an investigator-led program to support independent, physician-driven research on pulmonary embolism.
The partners said the initiative aims to close evidence gaps in pulmonary embolism care, particularly where limited real-world data can constrain clinical decision-making. The fund is structured to back studies designed and led by investigators, with a focus that can include patient outcomes, workflow optimization, and novel therapeutic approaches intended to improve real-world pulmonary embolism care.
The program will award grants ranging from $50,000 to $750,000 over one to three years, with the stated goal of supporting both established and emerging investigators. Applicants are invited to submit a brief letter of intent outlining study objectives, design, and budget, and selected applicants will be asked to submit full proposals for review.
The announcement cited the scale of the clinical burden, noting pulmonary embolism affects about one in 1,000 people annually and is estimated to contribute to more than 50,000 deaths each year in the United States. Against that backdrop, AngioDynamics and The PERT Consortium positioned the ALPHA-PE Research Fund as a mechanism to accelerate the generation of clinically relevant evidence intended to inform care delivery and advance pulmonary embolism management.
KEY QUOTES
“This initiative reflects our commitment to supporting the cardiovascular community in closing critical data gaps in pulmonary embolism care. By supporting investigator-led studies, we strengthen the evidence base for approaches that can improve patient outcomes and advance the standard of care.”
Laura Piccinini, Senior Vice President and General Manager, Cardiovascular & International, AngioDynamics
“Independent, physician-led research plays a critical role in generating real-world insight in treating pulmonary embolism. The ALPHA-PE Research Fund is designed to foster science-driven collaboration that advances understanding and care for patients.”
Juan Carlos Serna, Senior Vice President of Scientific & Clinical Affairs, AngioDynamics
“We are incredibly excited about this collaboration and the opportunity it creates for the PE community. Physician-led, investigator-driven research is essential to closing critical evidence gaps in pulmonary embolism care. The ALPHA-PE Research Fund represents a meaningful investment in supporting innovation, fostering collaboration, and advancing impactful research that will directly inform real-world practice and improve patient outcomes.”
Amir Darki, MD, Co-Chair, National PERT Research Consortium
